Cargando…

In Vivo MRI Tracking of Tumor Vaccination and Antigen Presentation by Dendritic Cells

Cancer vaccination using tumor antigen-primed dendritic cells (DCs) was introduced in the clinic some 25 years ago, but the overall outcome has not lived up to initial expectations. In addition to the complexity of the immune response, there are many factors that determine the efficacy of DC therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Bulte, Jeff W. M., Shakeri-Zadeh, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477715/
https://www.ncbi.nlm.nih.gov/pubmed/34581954
http://dx.doi.org/10.1007/s11307-021-01647-4
_version_ 1784575900812050432
author Bulte, Jeff W. M.
Shakeri-Zadeh, Ali
author_facet Bulte, Jeff W. M.
Shakeri-Zadeh, Ali
author_sort Bulte, Jeff W. M.
collection PubMed
description Cancer vaccination using tumor antigen-primed dendritic cells (DCs) was introduced in the clinic some 25 years ago, but the overall outcome has not lived up to initial expectations. In addition to the complexity of the immune response, there are many factors that determine the efficacy of DC therapy. These include accurate administration of DCs in the target tissue site without unwanted cell dispersion/backflow, sufficient numbers of tumor antigen-primed DCs homing to lymph nodes (LNs), and proper timing of immunoadjuvant administration. To address these uncertainties, proton ((1)H) and fluorine ((19)F) magnetic resonance imaging (MRI) tracking of ex vivo pre-labeled DCs can now be used to non-invasively determine the accuracy of therapeutic DC injection, initial DC dispersion, systemic DC distribution, and DC migration to and within LNs. Magnetovaccination is an alternative approach that tracks in vivo labeled DCs that simultaneously capture tumor antigen and MR contrast agent in situ, enabling an accurate quantification of antigen presentation to T cells in LNs. The ultimate clinical premise of MRI DC tracking would be to use changes in LN MRI signal as an early imaging biomarker to predict the efficacy of tumor vaccination and anti-tumor response long before treatment outcome becomes apparent, which may aid clinicians with interim treatment management.
format Online
Article
Text
id pubmed-8477715
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-84777152021-09-28 In Vivo MRI Tracking of Tumor Vaccination and Antigen Presentation by Dendritic Cells Bulte, Jeff W. M. Shakeri-Zadeh, Ali Mol Imaging Biol Review Article Cancer vaccination using tumor antigen-primed dendritic cells (DCs) was introduced in the clinic some 25 years ago, but the overall outcome has not lived up to initial expectations. In addition to the complexity of the immune response, there are many factors that determine the efficacy of DC therapy. These include accurate administration of DCs in the target tissue site without unwanted cell dispersion/backflow, sufficient numbers of tumor antigen-primed DCs homing to lymph nodes (LNs), and proper timing of immunoadjuvant administration. To address these uncertainties, proton ((1)H) and fluorine ((19)F) magnetic resonance imaging (MRI) tracking of ex vivo pre-labeled DCs can now be used to non-invasively determine the accuracy of therapeutic DC injection, initial DC dispersion, systemic DC distribution, and DC migration to and within LNs. Magnetovaccination is an alternative approach that tracks in vivo labeled DCs that simultaneously capture tumor antigen and MR contrast agent in situ, enabling an accurate quantification of antigen presentation to T cells in LNs. The ultimate clinical premise of MRI DC tracking would be to use changes in LN MRI signal as an early imaging biomarker to predict the efficacy of tumor vaccination and anti-tumor response long before treatment outcome becomes apparent, which may aid clinicians with interim treatment management. Springer International Publishing 2021-09-28 2022 /pmc/articles/PMC8477715/ /pubmed/34581954 http://dx.doi.org/10.1007/s11307-021-01647-4 Text en © World Molecular Imaging Society 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Bulte, Jeff W. M.
Shakeri-Zadeh, Ali
In Vivo MRI Tracking of Tumor Vaccination and Antigen Presentation by Dendritic Cells
title In Vivo MRI Tracking of Tumor Vaccination and Antigen Presentation by Dendritic Cells
title_full In Vivo MRI Tracking of Tumor Vaccination and Antigen Presentation by Dendritic Cells
title_fullStr In Vivo MRI Tracking of Tumor Vaccination and Antigen Presentation by Dendritic Cells
title_full_unstemmed In Vivo MRI Tracking of Tumor Vaccination and Antigen Presentation by Dendritic Cells
title_short In Vivo MRI Tracking of Tumor Vaccination and Antigen Presentation by Dendritic Cells
title_sort in vivo mri tracking of tumor vaccination and antigen presentation by dendritic cells
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477715/
https://www.ncbi.nlm.nih.gov/pubmed/34581954
http://dx.doi.org/10.1007/s11307-021-01647-4
work_keys_str_mv AT bultejeffwm invivomritrackingoftumorvaccinationandantigenpresentationbydendriticcells
AT shakerizadehali invivomritrackingoftumorvaccinationandantigenpresentationbydendriticcells